Generation of anti-idiotype antibodies for application in clinical immunotherapy laboratory analyses

Zhanqi Liu, Con Panousis, Fiona E Smyth, Roger Murphy, Veronika Wirth, Glenn A Cartwright, Terrance Grant Johns, Andrew M Scott

Research output: Contribution to journalArticleResearchpeer-review

16 Citations (Scopus)


The chimeric monoclonal antibody ch806 specifically targets the tumor-associated mutant epidermal growth factor receptor (de 2-7EGFR or EGFRVIII) and is currently under investigation for its potential use in cancer therapy. The humanised monoclonal antibody hu3S193 specifically targets the Lewis Y epithelial antigen and is currently in Phase I clinical trials in patients with advanced breast, colon, and ovarian carcinomas. To assist the clinical evaluation of ch806 and hu3S193, laboratory assays are required to monitor their serum pharmacokinetics and quantitate any immune responses to the antibodies. Mice immunized with ch806 or hu3S193 were used to generate hybridomas producing antibodies with specific binding to ch806 or hu3S193 and competitive for antigen binding. These anti-idiotype antibodies (designated Ludwig Melbourne Hybridomas, LMH) were investigated as reagents suitable for use as positive controls for HAHA or HACA analyses and for measuring hu3S193 or ch806 in human serum. Anti-idiotypes with the ability to concurrently bind two target antibody molecules were identified, which enabled the development of highly reproducible, sensitive, specific ELISA assays for determining serum concentrations of hu3S193 and ch806 with a 3 ng/mL limit of quantitation using LMH-3 and LMH-12, respectively.
Original languageEnglish
Pages (from-to)219 - 228
Number of pages10
Issue number4
Publication statusPublished - 2003
Externally publishedYes

Cite this